Patent ID: 8663635

Claim:
A method of treating a prostate cancer or bladder cancer patient, comprising the steps of: (a) obtaining a test tissue sample from an individual having a prostate or bladder cancer that expresses a N-cadherin protein of SEQ ID NO:1 or a neuronal N-cadherin of SEQ ID NO:3, wherein the test tissue sample comprises cancer cells and wherein the cancer is a prostate cancer or a bladder cancer; (b) determining whether expression of the N-cadherin of SEQ ID NO:1 or the neuronal N-cadherin of SEQ ID NO:3 is increased in at least a subset of the cells in the test tissue sample in comparison to the level of expression of the N-cadherin of SEQ ID NO:1 or the neuronal N-cadherin of SEQ ID NO:3 in a control tissue sample from an individual known to be negative for the prostate cancer and bladder cancer; and (c) administering an effective amount of an antibody that binds a N-cadherin protein of SEQ ID NO:1 or a neuronal N-cadherin of SEQ ID NO:3, or an antigen-binding fragment thereof, to the individual having a prostate cancer or bladder cancer that has increased expression of the N-Cadherin protein of SEQ ID NO:1 or a neuronal N-cadherin of SEQ ID NO:3 in comparison to the control tissue sample.